Clinical Trials - March 28, 2022
Vicore strengthens its rare lung disease pipeline
Vicore Pharma Holding has announced plans to initiate a clinical trial with C21 in Pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a rare lung disease with huge unmet medical need where existing medicines reduce the pressure by dilating the vessels without changing underlying disease or survival, describes the company. Both PAH and the pulmonary […]
Clinical Trials - February 11, 2022
Vicore Pharma announces new data
Vicore Pharma has announced data from an interim analysis suggesting that C21 stabilizes disease and increases lung function in idiopathic pulmonary fibrosis (IPF) patients as quantified by standard FVC (Forced Vital Capacity) measurement. An interim analysis of the phase 2 proof-of-concept study in IPF (the AIR1study) showed an initial stabilization of disease and then an […]
COVID-19 - September 22, 2021
Vicore Pharma obtains patent in the USA
Vicore Pharma has announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2. “COVID-19 may be just a few mutations away from evading existing vaccines, and we know that even vaccinated people can […]
Drug Development Pharma - April 23, 2019
Vicore Pharma announces second indication for VP01
The company has selected diffuse systemic sclerosis (dSSc) as the second indication for its lead program VP01 (C21), which complements the primary indication, idiopathic pulmonary fibrosis (IPF). Diffuse systemic sclerosis is a disease with a strong involvement of angiotensin II and an upregulation of the angiotensin II type 2 receptor (AT2R – the C21 target), […]
